What Is The Leading Driver Behind Rising Breast Cancer Incidence Drives Growth Of The Market Market Expansion in 2025

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the HER2-Negative Breast Cancer Industry Market Size Be by 2025?
The market valuation for her2-negative breast cancer has recently experienced robust expansion, projected to elevate from $16.29 billion in the year 2024 to $17.57 billion by 2025, reflecting a compound annual growth rate (CAGR) of 7.8%. This upward trajectory across the historical timeframe is fundamentally driven by several key factors, including a surge in incidences of breast cancer, heightened public consciousness regarding the disease, amplified expenditures within the healare sector, the demographic shift towards an older population structure, and the broad development of medical infrastructure.

What's the Long-Term Growth Forecast for the HER2-Negative Breast Cancer Market Size Through 2029?
Anticipation surrounds the her2-negative breast cancer sector, projecting robust expansion through the upcoming years; this market is slated to reach a valuation of $23.67 billion by 2029, fueled by a compound annual growth rate (CAGR) of 7.7%. This upward trajectory during the projection timeframe is largely credited to several contributing factors: greater alcohol consumption, a rise in less healthy lifestyle choices, growing obesity rates, increased tobacco usage, and a persistent demand for superior therapeutic options. Key developments poised to shape this period encompass novelties in diagnostic tools, the incorporation of specific targeted treatments, wider use of immunotherapies, significant regulatory clearances from the FDA, and overall technological progress.

View the full report here:
https://www.thebusinessresearchcompany.com/report/her2-negative-breast-cancer-global-market-report

What Are the Key Growth Drivers Fueling the HER2-Negative Breast Cancer Market Expansion?
The escalating frequency of breast cancer diagnoses is anticipated to fuel the expansion of the HER2-negative breast cancer sector moving ahead. Breast cancer is fundamentally a condition marked by the unchecked proliferation of atypical cells within the mammary gland, typically commencing within the milk ducts or lobules. This heightened occurrence rate stems from various elements, such as greater public consciousness and enhanced diagnostic procedures, resulting in earlier identification and more regular testing. HER2-Negative Breast Cancer holds significant importance in progressing oncology studies by offering perspectives on unique tumor characteristics and therapeutic approaches, thereby facilitating the creation of more precise treatments for afflicted individuals. Illustratively, data from the Centers for Disease Control and Prevention, a US regulatory body, indicated that in 2021, 272,454 new instances of female breast cancer were documented across the United States, and by 2022, the disease claimed the lives of 42,211 women. Consequently, the increasing prevalence of breast cancer cases serves as a primary impetus for the growth observed in the HER2-negative breast cancer market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21203&type=smp

What Are the Key Trends Driving HER2-Negative Breast Cancer Market Growth?
Key corporations participating in the HER2-negative breast cancer sector are prioritizing the attainment of official authorizations to launch novel therapies, broaden their offerings, and strengthen their competitive standing. Regulatory clearance signifies the formal sanction provided by governing bodies, permitting firms to commercialize and dispense pharmaceuticals or medical interventions once they have satisfied prerequisites for safety, effectiveness, and high quality. To illustrate, during October of 2024, Genentech Inc., a biotechnology entity situated in the United States, successfully obtained authorization from the FDA for Itovebi (inavolisib), a targeted therapy designated for advanced cases of hormone receptor-positive (HR+), HER2-negative breast cancer characterized by a PIK3CA mutation. This sanction enables the utilization of Itovebi alongside palbociclib and fulvestrant, demonstrating substantial gains in the time before disease progression for patients when contrasted with existing standard care protocols. This newly sanctioned combination introduces a crucial alternative for individuals confronting restricted therapeutic avenues, thereby underscoring the necessity of biomarker analysis to pinpoint the precise patient group likely to derive maximum advantage from this specific intervention.

How Is the HER2-Negative Breast Cancer Market Segmented?
The her2-negative breast cancermarket covered in this report is segmented -

1) By Treatment Type: Chemotherapy; Hormone Therapy; Targeted Therapy; Immunotherapy
2) By Cancer Stage: Early Stage; Locally Advanced Stage; Metastatic Stage
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Subsegments:
1) By Chemotherapy: Anthracyclines; Taxanes; Platinum-Based Chemotherapy; Alkylating Agents; Antimetabolites
2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Selective Estrogen Receptor Degraders (SERDs)
3) By Targeted Therapy: CDK4/6 Inhibitors; PI3K Inhibitors; PARP Inhibitors
4) By Immunotherapy: Immune Checkpoint Inhibitors; Tumor-Infiltrating Lymphocyte (TIL) Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21203&type=smp

Which Companies Are Leading the Charge in HER2-Negative Breast Cancer Market Innovation?
Major companies operating in the HER2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

Which Regions Are Leading the Global HER2-Negative Breast Cancer Market in Revenue?
North America was the largest region in the HER2-negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-negative breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21203

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.